These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9030468)

  • 21. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.
    Rehermann B; Thimme R
    Gastroenterology; 2019 Jan; 156(2):369-383. PubMed ID: 30267712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of HBV HCV co-infection: exceeded response].
    Barbosa J; Calinas F
    Acta Med Port; 2011; 24(1):199-202. PubMed ID: 21672459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of antiviral therapy on the cellular immune response in acute hepatitis C.
    Rahman F; Heller T; Sobao Y; Mizukoshi E; Nascimbeni M; Alter H; Herrine S; Hoofnagle J; Liang TJ; Rehermann B
    Hepatology; 2004 Jul; 40(1):87-97. PubMed ID: 15239090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pathogenesis and alpha-2 interferon treatment of chronic hepatitis B].
    Pirotte J
    Rev Med Liege; 1996 Aug; 51(8):514-21. PubMed ID: 8927872
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence.
    Biliotti E; Zacharia S; Grieco S; Spaziante M; Giusto M; Merli M; Gallinaro V; Taliani G
    J Chemother; 2012 Dec; 24(6):369-72. PubMed ID: 23174103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
    Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
    Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of human immunodeficiency virus on viral hepatitis.
    Mallet V; Vallet-Pichard A; Pol S
    Liver Int; 2011 Jan; 31 Suppl 1():135-9. PubMed ID: 21205151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.
    Marinos G; Naoumov NV; Williams R
    Hepatology; 1996 Nov; 24(5):991-5. PubMed ID: 8903365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of interferon-mediated antiviral immunity by hepatitis B virus: an overview of research progress.
    Guo P
    Scand J Immunol; 2013 Sep; 78(3):230-7. PubMed ID: 23790137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents.
    Mutchnick MG; Ehrinpreis MN; Kinzie JL; Peleman RR
    Antiviral Res; 1994 Jul; 24(2-3):245-57. PubMed ID: 7526795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients.
    Liu CJ; Chen PJ; Lai MY; Kao JH; Jeng YM; Chen DS
    Hepatology; 2003 Mar; 37(3):568-76. PubMed ID: 12601355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy.
    Liaw YF; Chien RN; Lin SM; Yeh CT; Tsai SL; Sheen IS; Chu CM
    J Interferon Cytokine Res; 1997 Aug; 17(8):449-52. PubMed ID: 9282824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of hepatitis B virus populations in an interferon-alpha-treated patient reveals predominant mutations in the C-gene and changing e-antigenicity.
    Günther S; Paulij W; Meisel H; Will H
    Virology; 1998 Apr; 244(1):146-60. PubMed ID: 9581787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of efficacy and safety of thymus humoral factor-gamma 2 in the management of chronic hepatitis B.
    Farhat BA; Marinos G; Daniels HM; Naoumov NV; Williams R
    J Hepatol; 1995 Jul; 23(1):21-7. PubMed ID: 8530805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
    Urganci N; Gulec S; Dogan S; Nuhoglu A
    Int J Infect Dis; 2006 Nov; 10(6):453-7. PubMed ID: 17000127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The A, B, Cs of viral hepatitis in the biologic era.
    Ferri C; Govoni M; Calabrese L
    Curr Opin Rheumatol; 2010 Jul; 22(4):443-50. PubMed ID: 20386453
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Liver, biliary tracts and human immunodeficiency virus infection. 1:q liver, HIV and hepatitis B, C and D viruses].
    Vuitton DA; Chossegros P; Bresson-Hadni S; Delfraissy JF; Kirn A; Marcellin P; Pol S; Saint-Paul MC
    Gastroenterol Clin Biol; 1996; 20(3):269-80. PubMed ID: 8763066
    [No Abstract]   [Full Text] [Related]  

  • 40. Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2.
    Stancek D; Fuchsberger N; Oltman M; Schmeisser H; Kontsek P; Jahnová E; Hajnická V
    Acta Virol; 2001; 45(5-6):287-92. PubMed ID: 12083327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.